Skip NavigationSkip to Content
Return Return to Search Results

Efficiency of human immunodeficiency virus type 1 postentry infection processes: Evidence against disproportionate numbers of defective virions

  1. Author:
    Thomas, J. A.
    Ott, D. E.
    Gorelick, R. J.

  2. Author Address

    SAIC Frederick Inc, Natl Canc Inst, Basic Res Program, AIDS Vaccine Program, Frederick, MD 21702 USA.;Gorelick, RJ, SAIC Frederick Inc, Natl Canc Inst, Basic Res Program, AIDS Vaccine Program, Bldg 535,4th Floor, Frederick, MD 21702 USA.;gorelick@ncifcrf.gov
    1. Year: 2007
    2. Date: Apr
  2. Journal: Journal of Virology
    1. 81
    2. 8
    3. Pages: 4367-4370
  4. Type of Article: Article
  5. ISSN: 0022-538X
  1. Abstract:

    The vast majority of human immunodeficiency virus type I particles are claimed to be noninfectious, but there is disagreement as to whether they are defective or simply lack the opportunity to initiate an infection. We have examined the efficiencies of reverse transcription and integration and find that approximately 1 of every 8 virions that initiate reverse transcription form proviruses, a quantity significantly different from the commonly reported ratio of I in 1,000. In addition, results from two different infectivity assays demonstrate that the titers are not equivalent to the number of infectious particles. The apparent predominance of noninfectious particles is due to infrequent occurrences of successful virus-cell interactions.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1128/jvi.02357-06
  3. View record in Web of Science®
  4. WOS: 000245692900070

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel